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Background: Several studies in the oncology literature have demonstrated the prognostic value of baseline quality
of life (QoL). We investigated whether changes in QoL could predict survival in prostate cancer patients.
Methods: We evaluated 250 prostate cancer patients treated at our institution between Jan 2001 and Dec 2009
who were available for a minimum follow-up of 3 months. QoL was evaluated at baseline and after 3 months of
treatment initiation using EORTC-QLQ-C30. Cox regression evaluated the prognostic significance of baseline and
changes in QoL scores after adjusting for relevant clinical and demographic variables.
Results: Median overall survival was 89.1 months (95% CI: 56.5-121.7). Baseline QoL scale predictive of survival upon
multivariate analysis was fatigue (p = 0.001). Associations between changes in QoL and survival, upon multivariate
analysis, were observed for dyspnea and cognitive functioning. Every 10-point increase (worsening) in dyspnea was
associated with a 16% increased risk of death (HR = 1.16; 95% CI = 1.02 to 1.30, p = 0.02), and every 10-point
increase (improvement) in cognitive functioning was associated with a 24% decreased risk of death (HR = 0.76; 95%
CI = 0.54 to 0.98, p = 0.04).
Conclusions: This study provides preliminary evidence to indicate that prostate cancer patients with better
baseline fatigue and patients whose dyspnea and cognitive functioning improves within 3 months of treatment are
at a significantly decreased risk of mortality.Background
Prostate cancer is the most common cancer in men in the
US [1-4]. It is also the second leading cause of cancer
death among US men after lung cancer [5]. Each year in
the US, approximately 220,000 new cases of prostate
cancer are diagnosed, and 30,000 men die of the disease
[6]. Global estimates suggest about 903,500 new cases and
258,400 deaths annually [7]. Despite its high morbidity,
the etiology of prostate cancer remains largely unknown
[5]. Tumor stage and Gleason score remain the two
most powerful prognostic factors in prostate cancer [8].
Advanced prostate cancer is associated with significant
morbidity, both from the underlying disease and associated
co-morbidities, and also from treatment toxicity, which
can profoundly affect patient quality of life (QoL) [9].
QoL is a multidimensional construct that includes
physical, social, psychological and functional domains at
the very least. Symptom palliation and QoL improvement* Correspondence: digant.gupta@ctca-hope.com
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reproduction in any medium, provided the orhave gained prominence in the assessment of new treat-
ments, and the prolongation of life is no longer the sole
aim of therapy [9]. This has led to the inclusion of QoL
assessment as a primary endpoint in cancer clinical trials
along with traditional endpoints of tumor response and
survival. QoL measurements can provide information
about the impact of the disease and its treatment to aid
physicians in selecting both antineoplastic and supportive
care therapy.
Baseline or pretreatment QoL has been shown to be a
prognostic indicator in prostate cancer in previously
published studies [10-13]. However, to the best of our
knowledge, there is no study in the literature investigat-
ing the prognostic impact of changes in QoL scores on
survival in prostate cancer, whether this is assessed at
the time of initial cancer diagnosis or following disease
relapse. In the current study, we investigated whether
pretreatment QoL parameters as well as changes in QoL
scores from baseline until 3 months after treatment initi-
ation could predict survival in patients with prostate
cancer. This study builds upon our previous work in thistd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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QoL and survival in other types of cancers [14-16].
Methods
Study population
We examined 250 histologically confirmed prostate cancer
patients treated at Cancer Treatment Centers of America®
(CTCA) at Midwestern (MRMC) and Southwestern
(SRMC) Regional Medical Centers between Jan 2001 and
Dec 2009. The inclusion criteria for participation in this
study were a histological diagnosis of prostate cancer
and the ability to read English. Patients with all stages
of prostate cancer were eligible for the study. Patients
were excluded if they were unable to give informed
consent or were unable to understand or cooperate
with study conditions.
A trained clinical coordinator was responsible for de-
termining eligibility, describing the study, and obtaining
informed consent. All patients were assured that refusal
to participate would not affect their future care in any
way. Patients who chose to participate were presented
with the questionnaire at their initial visit and instructed
to return their completed questionnaires to the clinical
coordinator within 24 hours. Thus, patients completed
questionnaires prior to receiving therapy at our facility.
Additional patient data recorded for this study was
age, stage of disease at diagnosis, prior treatment history
(previously treated versus newly diagnosed) and treatment
received at our institution. The only follow-up information
required was the date of death or the date of last contact/
last known to be alive, obtained from the tumor registries
at Midwestern and Southwestern Regional Medical
Centers. This study was approved by the Institutional
Review Board at CTCA.
QoL assessment
European Organization for the Research and Treatment
of Cancer Quality of Life Questionnaire (QLQ-C30) was
used to assess patient QoL. It emphasizes a patient’s
capacity to fulfill the activities of daily living. It is a 30-
item cancer specific questionnaire that incorporates five
functioning scales (physical, role, cognition, emotional,
and social), eight symptom scales (fatigue, pain, and
nausea/vomiting, dyspnea, insomnia, loss of appetite,
constipation, diarrhea), financial well-being scale and a
global scale (based on two items: “how would you rate
your overall health during the past week” and “how would
you rate your overall quality of life during the past week”).
The raw scores are linearly transformed to give standard
scores in the range of 0–100 for each of the functioning
and symptom scales. Higher scores in the global and
functioning scales and lower scores in the symptom
scales indicate better QoL. A difference of 5–10 points
in the scores represents a small change, 10–20 points amoderate change and greater than 20 points a large,
clinically significant change from the patient’s perspec-
tive [17]. This instrument has been extensively tested
for reliability and validity [18-20]. QoL was assessed at
baseline and after 3 months of treatment initiation at
our institution.
Statistical analysis
Patient survival was the primary end point and defined
as the time interval between the date of first patient visit
to the hospital and the date of death from any cause or
the date of last contact/last known to be alive. Two
separate analyses were performed. First, the relationship
between baseline QoL and patient survival was investi-
gated for 250 patients. Second, the relationship between
change in QoL scores between baseline and 3 months
and survival was assessed for the same patient cohort.
Change scores were calculated by subtracting the base-
line scores from the 3-month QoL scores. The overall
survival was calculated using the Kaplan-Meier method.
Clinical and QoL variables were evaluated using univari-
ate Cox proportional hazards models to determine which
parameters showed individual prognostic value for sur-
vival. Multivariate Cox proportional hazards models were
then performed to evaluate the joint prognostic signifi-
cance of all QoL and clinical factors. Each QLQ-C30 scale
was treated as a continuous variable for the purpose of
Cox regression analyses. The effect of QoL parameters
on patient survival was expressed as hazard ratios
(HRs) with 95% confidence intervals (CIs). Changes of 10
or more points on a 0 to 100 scale are considered clinically
relevant [21], therefore, we present hazard ratios for a
10-point change on the continuous QoL variables. An
effect was considered to be statistically significant if the p
value was less than or equal to 0.05. All statistical tests
were two-sided. All data were analyzed using IBM SPSS
version 20.0 (IBM, Armonk, NY, USA).
Cox regression with time-independent covariates as-
sumes that the ratio of hazards for any two groups re-
mains constant in proportion over time. We checked this
assumption by examining log-minus-log plots for the
categorical predictors. For continuous predictors, this
assumption was checked using an extended Cox model
with time-dependent covariates. Potential multicollinearity
was assessed in two steps. Large values (above 0.75) of
Pearson’s correlation coefficients were used as an initial
screen for pairs of QoL variables. As a second check, the
variance inflation factor was used with the final model to
verify that multicollinearity was not significantly influen-
cing model coefficients [22,23]. In order to minimize
instability of the final multivariate model resulting from
high multicollinearity, global QoL was evaluated separately
because it is most highly correlated with all other variables
on the QLQ-C30 questionnaire, and also because it is
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to assess the possible influence of sample bias on the
results as well as to investigate the stability of the
model coefficients, we performed a bias-corrected and
accelerated (BCa) bootstrap resampling procedure. We
generated 1000 samples, each the same size as the ori-
ginal data set, by random selection with replacement.
Cox regression was then run separately on these 1000
samples to obtain robust estimates of the standard er-
rors of coefficients, and hence the p values and 95%
BCa confidence intervals of the model coefficients [24].Table 2 Baseline quality of life scores stratified by prior
treatment history
Baseline Newly diagnosed Previously treated PResults
Patient characteristics
Table 1 describes the baseline characteristics of our pa-
tient cohort. At the time of this analysis, 39 deaths had
occurred among the 250 participants. Majority of the
patients were newly diagnosed with stage II disease.
The proportion of patients receiving chemotherapy,
radiotherapy, hormone therapy and surgery at our in-
stitution were 12%, 74.8%, 66% and 1.2% respectively.
Chemotherapy received at our institution was highly
correlated with prior treatment history such that 4% of
newly diagnosed versus 23.8% of previously treated
patients received chemotherapy (chi-square p <0.001).
Similarly, 85.9% of newly diagnosed versus 58.4% ofTable 1 Baseline characteristics of 250 prostate
cancer patients
Characteristic Categories Number Percent
Age at diagnosis (years) ▪ Mean 59.7
▪ Median 59.0
▪ Range 37-79
Vital status ▪ Death 39 15.6
▪ Alive 211 84.4
Treatment history ▪ Newly diagnosed 149 59.6
▪ Previously treated 101 40.4
Stage at diagnosis ▪ Stage I 3 1.2
▪ Stage II 168 67.2
▪ Stage III 31 12.4
▪ Stage IV 48 19.2
Chemotherapy at CTCA ▪ No 220 88.0
▪ Yes 30 12.0
Radiotherapy at CTCA ▪ No 63 25.2
▪ Yes 187 74.8
Hormone therapy at CTCA ▪ No 85 34.0
▪ Yes 165 66.0
Surgery at CTCA ▪ No 247 98.8
▪ Yes 3 1.2previously treated patients received radiotherapy at our
institution (chi-square p <0.001).
Table 2 displays the baseline QoL scores across the
two categories of prior treatment history. Patients with
newly diagnosed disease had statistically significantly
better QoL compared to patients who were previously
treated for all QoL scales except for insomnia, diarrhea
and financial scales.
Table 3 describes the results of univariate Cox regres-
sion analysis for baseline patient characteristics. Treat-
ment history and stage at diagnosis were significantly
associated with survival while age was not. Median over-
all survival for the entire patient cohort was 89.1 months
(95% CI: 56.5-121.7 months). The median survival for
newly diagnosed and previously treated disease was 82.7
and 41.3 months respectively, log-rank p <0.001. The
median survival for stages I-II and stages III-IV was 81.9
and 48.0 months respectively, log-rank p <0.001.
Association between baseline quality of life and survival
Table 4 describes the baseline scores for all dimensions
of EORTC QLQ-C30 instrument. Among the EORTC







Global 70.7 (23.6) 58.4 (27.1) <0.001*
General
function
Physical 88.5 (17.9) 79.0 (23.2) <0.001*
Role 86.9 (24.5) 74.0 (31.3) <0.001*
Emotional 77.0 (22.7) 70.7 (24.2) 0.04*
Cognitive 85.3 (21.4) 79.2 (22.6) 0.03*
Social 85.1 (24.2) 73.1 (29.6) 0.001*
General
symptom
Fatigue 23.4 (25.9) 36.4 (26.2) <0.001*
Nausea/Vomiting 4.2 (12.2) 8.0 (17.4) 0.04*
Pain 16.5 (23.6) 31.1 (32.7) <0.001*
Dyspnea 12.7 (21.0) 18.4 (23.7) 0.04*
Insomnia 27.2 (28.2) 32.0 (30.8) 0.21
Appetite loss 10.1 (21.1) 16.1 (25.2) 0.04*
Constipation 8.0 (18.4) 16.1 (25.6) 0.004*
Diarrhea 8.5 (18.2) 8.5 (19.2) 0.97
Financial 17.7 (29.0) 25.4 (31.6) 0.09
*P < 0.05.
Table 3 Baseline characteristics and associated HRs
for death
Characteristic HR (95% CI) P















*HRs correspond to a 10-point increment for age.
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(best) mean score of 84.6 was recorded for physical
functioning. Among the EORTC QLQ-C30 symptom
scales, nausea/vomiting had the lowest (best) mean score
of 5.8 while the highest (worst) mean score of 29.2 was
recorded for insomnia. Table 4 also displays the results
of univariate and multivariate Cox regression analyses
for each QoL variable. The HRs along with their 95%
CIs for every 10-point increase in all EORTC QLQ-C30
scales are given. On univariate analysis, several baseline
QoL variables were predictive of survival: global, phys-







General quality of life
Global 65.8 (25.7) 0.85 (0.74 – 0.9
General function
Physical 84.6 (20.7) 0.81 (0.70 – 0.9
Role 81.7 (28.1) 0.87 (0.78 – 0.9
Emotional 74.5 (23.5) 0.98 (0.85 – 1.1
Cognitive 82.8 (22.1) 1.02 (0.88 – 1.1
Social 80.2 (27.1) 0.90 (0.80 – 1.0
General symptom
Fatigue 28.6 (26.8) 1.16 (1.06 – 1.2
Nausea/Vomiting 5.8 (14.6) 1.12 (0.98 – 1.2
Pain 22.4 (28.5) 1.16 (1.06 – 1.2
Dyspnea 15.0 (22.3) 0.98 (0.83 – 1.1
Insomnia 29.2 (29.3) 1.01 (0.90 – 1.1
Appetite loss 12.5 (23.0) 1.11 (1.01– 1.22
Constipation 11.3 (21.9) 1.18 (1.07 – 1.2
Diarrhea 8.5 (18.6) 0.98 (0.82 – 1.1
Financial 21.4 (30.2) 1.04 (0.95 – 1.1
• HRs correspond to a 10-point increment for QoL scores.
• 2 sets of multivariate models were constructed: one for global QoL and other for
• Multivariate model (for general function and symptom variables combined) adjust
QoL variables.
• Multivariate model for global QoL adjusted for prior treatment history and stage a
• *P < 0.05.Before proceeding with multivariate analysis, we checked
the bivariate Pearson’s correlation among the QoL vari-
ables to screen for observable multicollinearity. All cor-
relation coefficients were smaller than the pre-decided
cut-off level of r = 0.75. As a result, all QoL variables
were considered in the multivariate analysis. On mul-
tivariate analysis, after adjusting for prior treatment
history and stage at diagnosis, only fatigue was found
to be statistically significantly associated with survival.
A separate multivariate model was run for global QoL
after adjusting for prior treatment history and stage at
diagnosis. Global QoL was not found to be significantly
associated with survival. VIF values for baseline QoL
variables ranged from 1.1 (diarrhea) to 4.0 (fatigue), none
of which indicates a significant problem with multicolli-
nearity [22,23]. There was no evidence of non-proportional
hazards in the multivariate models presented.
In order to further investigate the stability of the clas-
sical multivariate Cox models reported in Table 4, we
conducted a bootstrap resampling procedure based on
1000 samples. The bootstrap estimates of the multivari-
ate HRs along with corresponding p values and 95% BCa
CIs were calculated. We found no significant differencesnivariate Multivariate
P HR (95% CI) P
6) 0.007* 0.92 (0.80 – 1.04) 0.19
2) 0.001* 0.83 (0.64 – 1.03) 0.09
6) 0.006* 1.12 (0.88 – 1.37) 0.32
1) 0.78 0.97 (0.73 – 1.22) 0.84
7) 0.74 1.36 (0.99 – 1.51) 0.07
1) 0.08 1.04 (0.84 – 1.24) 0.72
7) 0.002* 1.45 (1.19 – 1.73) 0.001*
6) 0.08 0.88 (0.55 – 1.23) 0.50
6) 0.001* 1.09 (0.92 – 1.26) 0.31
3) 0.78 0.88 (0.71 – 1.05) 0.17
3) 0.82 0.99 (0.82 – 1.16) 0.89
) 0.04* 0.98 (0.75 – 1.21) 0.85
8) 0.001* 1.12 (0.96 – 1.27) 0.13
5) 0.85 1.02 (0.85 – 1.20) 0.79
4) 0.36 0.91 (0.74 – 1.08) 0.27
all general function and symptom variables combined.
ed for prior treatment history, stage at diagnosis and all baseline
t diagnosis.
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values between the classical Cox regression and boot-
strap Cox regression models (results not shown in the
interest of space).
Association between changes in quality of life and survival
Table 5 describes the change in scores from baseline
to 3 months for all dimensions of EORTC QLQ-C30
instrument. On an average, they were small. Table 5
also displays the results of univariate and multivariate
Cox regression analyses for change in QoL scores. On
univariate analysis, no change variable was significantly
predictive of survival. Before proceeding with multivariate
analysis, we checked the bivariate Pearson’s correlation
among the change scores to screen for observable multi-
collinearity. All correlation coefficients were smaller than
the pre-decided cut-off level of r=0.75. As a result, all QoL
change variables were considered in the multivariate
analysis. On multivariate analysis, after adjusting for prior
treatment history and stage at diagnosis, the change vari-
ables that were significantly predictive of survival were
cognitive functioning and dyspnea. A separate multivariate







General quality of life
Global −1.9 (28.3) 1.01 (0.90 – 1
General function
Physical −2.0 (22.7) 1.10 (0.98 – 1
Role −4.3 (33.4) 1.07 (0.99 – 1
Emotional 3.8 (25.2) 0.95 (0.84 – 1
Cognitive 1.1 (24.6) 0.92 (0.80 – 1
Social −1.6 (31.9) 1.06 (0.97 – 1
General symptom
Fatigue 2.8 (29.7) 0.94 (0.84 – 1
Nausea/Vomiting 2.8 (22.3) 0.95 (0.82 – 1
Pain 0.6 (31.0) 0.94 (0.84 – 1
Dyspnea 1.2 (26.7) 1.09 (0.98 – 1
Insomnia −2.5 (34.0) 0.96 (0.87 – 1
Appetite loss 0.9 (28.2) 1.01 (0.90 – 1
Constipation 0.6 (25.6) 0.94 (0.82 – 1
Diarrhea 2.0 (25.5) 0.99 (0.87 – 1
Financial 3.4 (34.9) 1.0 (0.91 – 1.
• HRs correspond to a 10-point increment for QoL scores.
• 2 sets of multivariate models were constructed: one for global QoL and other for
• Multivariate model (for change in general function and symptom variables combin
change variables.
• Multivariate model for change in global QoL adjusted for prior treatment history a
• *P <0.05.for prior treatment history and stage at diagnosis. Change
in global score was not found to be significantly associated
with survival. VIF values for change in QoL variables
ranged from 1.1 (change in diarrhea) to 3.3 (change in
fatigue), none of which indicates a significant problem
with multicollinearity. There was no evidence of non-pro-
portional hazards in the multivariate models presented.
In order to further investigate the stability of the clas-
sical multivariate Cox models reported in Table 5, we
conducted a bootstrap resampling procedure based on
1000 samples. The bootstrap estimates of the multivari-
ate HRs along with corresponding p values and 95% BCa
CIs were calculated. We found no significant differences
in regression coefficients and their corresponding p
values between the classical Cox regression and boot-
strap Cox regression models (results not shown in the
interest of space).
We decided to explore the data further by conducting
separate multivariate analysis for newly diagnosed and
previously treated patients. In newly diagnosed patients,
none of the change variables was significantly predictive
of survival. However, in previously treated patients, cog-
nitive functioning was significantly predictive of survivalh
nivariate Multivariate
I) P HR (95% CI) P
.12) 0.80 0.96 (0.85 – 1.07) 0.46
.23) 0.09 1.15 (0.93 – 1.37) 0.19
.16) 0.09 0.92 (0.75 – 1.08) 0.31
.06) 0.36 0.91 (0.71 – 1.12) 0.39
.04) 0.16 0.76 (0.54 – 0.98) 0.04*
.15) 0.19 1.03 (0.87 – 1.20) 0.71
.05) 0.28 0.97 (0.94 – 1.20) 0.77
.08) 0.45 0.77 (0.56 – 1.03) 0.06
.04) 0.24 0.91 (0.73 – 1.09) 0.34
.19) 0.09 1.16 (1.02 – 1.30) 0.02*
.05) 0.36 0.92 (0.79 – 1.04) 0.19
.12) 0.82 1.03 (0.87 – 1.20) 0.68
.05) 0.28 0.97 (0.82 – 1.12) 0.69
.11) 0.88 0.94 (0.80 – 1.08) 0.38
08) 0.93 1.08 (0.97 – 1.20) 0.17
all general function and symptom variables combined.
ed) adjusted for prior treatment history, stage at diagnosis and all QoL
nd stage at diagnosis.
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nitive functioning from baseline to 3 months was associ-
ated with a 41% decreased risk of death (HR = 0.59; 95%
CI = 0.27 to 0.93, p = 0.02).
Discussion
In this study, we found that prostate cancer patients
with better baseline fatigue and patients whose dyspnea
and cognitive functioning improves within 3 months of
treatment are at a significantly decreased risk of mortal-
ity. The association between baseline QoL and survival
in prostate cancer has been investigated and reported in
a few previously published studies [10-13].
A pooled analysis of data from three RCT’s of metastatic
hormone-resistant prostate cancer (HRPC) indicated
that bone scan result (P < 0.0001), hemoglobin level
(P < 0.0001), performance status (P = 0.0322), insomnia
(P = 0.002) and appetite loss (P = 0.0015) were independ-
ent predictors of survival [10]. A study by Sullivan et al. in
metastatic HRPC reported that patients with better base-
line HRQL have better predicted survival, time to disease
progression and pain prognosis than those with worse
HRQL. Change in HRQL (12-week) improved the predict-
ive accuracy for most clinical outcomes [13]. Lis et al.
found that baseline patient satisfaction with health and
physical subscale, psychological and spiritual subscale,
family subscale, and overall HRQL are predictive of sur-
vival in patients with prostate cancer. After adjusting for
the effects of treatment history and Gleason score, patient
satisfaction with health and physical subscale was found to
be significantly associated with survival (P = 0.04) [12]. In
an analysis of data from three randomized phase III multi-
center trials, Halabi et al. reported statistically significant
association between pain and survival in castration-
refractory prostate cancer (CRPC). The median survival
times were 17.6 months (95% CI, 16.1- 19.1 months) and
10.2 months (95% CI, 8.6- 11.3 months; P <.001) in men
with low (<17) and high (≥ 17) pain scores, respectively
[11]. Our current study takes the previous research in this
area to the next level by examining the impact of changes
in QoL scores (as opposed to simply assessing the baseline
QoL scores) on survival in prostate cancer patients under-
going treatment.
The results of this study have important implications
for both clinical and research practices. They suggest
that baseline QoL should be considered when planning
treatment and regular QoL assessment performed dur-
ing the course of treatment. Furthermore, interventions
aimed at improving specific QoL parameters should be
applied when indicated. The utility of this approach to
patient management, based on the findings described in
this study, would be validated definitively if interventions
that enhance specific QoL parameters are shown to en-
hance survival.Thus, the findings reported here suggest that QoL
monitoring, coupled with treatment to improve fatigue,
dyspnea and cognitive function when indicated, should
be investigated in prospective studies in prostate cancer.
Positive effects on survival as a consequence of interven-
tions designed specifically to improve patient symptoms
and QoL independent of tumor therapy would go a long
way towards establishing causative relationships between
specific QoL parameters and disease control. Although
some progress has been made with respect to the treat-
ment of fatigue in cancer patients, clinical effectiveness
is inconsistent and unpredictable. And there are at
present no effective means to address more complex
QoL factors such as global health. This challenges the
cancer research enterprise to develop greater under-
standing of the complex physiology responsible for all
aspects of QoL, and to use this information to develop
more effective and predictable methods to favorably
modulate this critical aspect of patient health and
wellness.
Several limitations of this study need to be acknowl-
edged. Our study, because of its retrospective nature,
relies on data not collected to test a specific hypothesis.
As a result, we could not control for certain factors in
our analyses that could influence survival such as treat-
ment received at our institution, medical co-morbidities,
socioeconomic factors, support system, exercise and
educational level. The patient cohort was limited only to
those patients who were English speakers and therefore
is not representative of the complete spectrum of pros-
tate cancer patients. A majority of our patients had stage
II disease at presentation to our hospital. As a result, we
acknowledge that our findings may not be applicable to
advanced-stage prostate cancer patients, an issue that
needs to be tested in suitable patient populations. More-
over, this study does not reveal a causative relationship
between QoL and survival. Rather, patient QoL was found
to act as a surrogate marker for otherwise undetected
prognostic factors [25]. QoL scores were assessed over a
3-month interval only which may not be sufficient time
for score changes to develop in other QoL parameters that
may be prognostic of survival. We did not control for the
multiple comparisons made in this study, but this is
acceptable for hypothesis-generating studies [26]. Finally,
we also think that restricting the analysis to newly diag-
nosed patients (patients with no prior treatment history)
would have been more accurate, as it would have allowed
for evaluation of true overall survival time, that is, time
from the date of diagnosis to the date of death. However,
doing so would have caused a significant reduction in the
sample size. In our study, the survival time was calculated
from the day of first visit at our hospital because QoL
information was not available at the time of diagnosis for
previously treated patients.
Gupta et al. BMC Urology 2013, 13:32 Page 7 of 7
http://www.biomedcentral.com/1471-2490/13/32/13/32This study also has several strengths, including no
missing data on any EORTC QLQ-C30 variables for the
entire study sample; the use of a valid and reliable QoL
instrument; the availability of clinical parameters in
nearly all patients; and availability of mature and reliable
survival data. As is the case for all exploratory retro-
spective studies, the most important outcome that can
be achieved is the development of a hypothesis sug-
gested by the results. As a consequence of this study, we
hypothesize that the parameters of fatigue, dyspnea and
cognitive function are independent determinants of sur-
vival in prostate cancer, and should be regularly assessed
and when indicated, targeted for intervention.
Conclusions
This exploratory study provides preliminary evidence to
indicate that prostate cancer patients with better base-
line fatigue and patients whose dyspnea and cognitive
functioning improves within 3 months of treatment have
a significantly increased probability of survival. Given
that QoL is as meaningful as the actual length of life in
patients with prostate cancer, these findings should be
used in clinical practice to systematically address QoL-
related problems of prostate cancer patients throughout
their treatment course.
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